SQA Regulatory Surveillance Summary | Monthly Update 2022 – July/August
SQA
OCTOBER 18, 2022
Patients who have been treated with a recalled drug should go to the hospital immediately if they develop difficulty breathing, chest pain, or confusion. Health Canada is monitoring the Taro Pharmaceuticals Inc.’s ’s recall and will inform the public if any new health risks are identified. PDA Technical Report No.
40 
Let's personalize your content